BioInvent International AB (BOVNF) Earnings Dates, Call Summary & Reports

Compare

4 Followers

Earnings Data

Report Date

Apr 29, 2026

Before Open (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

―

Last Year’s EPS

-0.2

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 26, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presents multiple strong clinical data points (notably BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL) with supportive safety and clear near-term catalysts and collaborations with Merck and AstraZeneca. Financially, Q4 sales fell sharply due to lower contract production while full-year sales increased materially driven by one-time items; operating costs and losses rose and the company states it is financed for only the next 12 months, meaning further financing or partnering will be needed to sustain a larger pivotal development plan. Overall, the positive clinical momentum and strategic partnerships outweigh short-term financial and execution risks, but upcoming readouts will be critical for de-risking future funding and pivotal starts.

Company Guidance

The management outlined a dense near‑term catalyst calendar and clear go/no‑go signals: clinical readouts are expected mid‑2026 (first Phase IIa BI‑1808+pembro in CTCL; additional BI‑1206 triplet NHL data) and in 2H‑2026 (further BI‑1808+pembro solid‑tumor data and first readout from BI‑1206+pembro in first‑line NSCLC and uveal melanoma), with concrete 2027 inflection points including completion of BI‑1808 monotherapy dose optimization in 1H‑2027 and potential pivotal starts (BI‑1808 pivotal in 2H‑2027; BI‑1206 NHL pivotal potentially 1H‑2027; BI‑1206 Phase IIb in NSCLC possibly 2H‑2027). Key clinical metrics already reported: BI‑1808 ovarian combo ORR 24% and disease control rate 57% (21 ovarian patients available), BI‑1808 CTCL monotherapy 46% ORR and 92% disease control in 13 evaluable CTCL patients (including a CR >1 year), BI‑1206 triplet in NHL ~80% ORR and 100% disease control (activity across follicular, marginal zone and mantle cell; current cohort ~30 patients), and a target benchmark of ~60% ORR for BI‑1206 in first‑line NSCLC to consider advancement. Financially, Q4‑2025 net sales were SEK 3m (vs SEK 21.4m a year earlier), full‑year net sales SEK 226m (vs SEK 45m), Q4 operating costs SEK 132m (Q4‑2024 SEK 147m), full‑year operating costs SEK 578m (2024 SEK 516m), Q4 result −SEK 125.8m and full‑year result −SEK 332.9m, with liquid funds/current investments of SEK 593m and the company assessed as financed for the coming 12 months.

Strong BI-1808 clinical efficacy in ovarian cancer (combo with pembrolizumab)

Phase IIa combination data in recurrent ovarian cancer: 24% overall response rate (ORR) and 57% disease control rate (DCR) with 21 evaluable ovarian cancer patients; dataset maturing with additional partial response and conversion of stable disease to PR, and a favorable safety profile.

Robust BI-1808 single-agent activity in T‑cell lymphoma (CTCL)

Monotherapy data in CTCL: 46% ORR and 92% DCR in 13 evaluable CTCL patients, with durable responses (including a complete response in Sézary Syndrome lasting >1 year); EMA orphan drug designation granted for BI-1808 in CTCL.

BI-1206 triplet shows high activity in non-Hodgkin lymphoma

Triplet (BI-1206 + rituximab + acalabrutinib) across follicular, marginal zone and mantle cell lymphoma: maintained ~80% ORR and 100% disease control rate; incremental 4 partial responses and 1 additional stable disease vs prior dataset, demonstrating activity across subtypes and encouraging duration.

Promising solid tumor signals for BI-1206 and advancement to first-line studies

Dose-escalation signals in PD-1/PD-L1 refractory solid tumors (complete and partial responses) supported opening a Phase IIa first-line program with pembrolizumab in non‑small cell lung cancer (NSCLC) and uveal melanoma; first readout expected H2 2026.

Strategic collaborations with large pharma

Supply and collaboration agreements in place with Merck (pembrolizumab combinations) and AstraZeneca (acalabrutinib supply for NHL), enabling first-line combination studies and providing strong external validation for programs.

Dense forward-looking clinical milestone timetable

Multiple near-term catalysts: additional BI-1808 combo and monotherapy Phase IIa readouts mid/late 2026; BI-1206 NHL update mid-2026; first-line BI-1206+KEYTRUDA readout H2 2026; potential pivotal starts in 2027 contingent on data.

Board strengthening and scientific depth

Two experienced board nominees (Kate Hermans, Scott Zinober) and publication of mechanistic/preclinical work that deepens scientific credibility and supports partnering discussions.

Improved full-year net sales (driven by one-time items) and short-term liquidity

Net sales for Jan–Dec 2025 were SEK 226 million vs SEK 45 million in 2024 (increase of SEK 181 million, ~+402%), driven mainly by a SEK 20 million payment (XOMA Royalty transaction) and a SEK 1 million milestone; liquid funds and current investments SEK 593 million at 31 Dec 2025 and company assessed as financed for the coming 12 months.

BioInvent International AB (BOVNF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BOVNF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 29, 2026	2026 (Q1)	- / -	-0.196	―	―	―
Feb 26, 2026	2025 (Q4)	- / -0.21	-0.196	-7.55% (-0.01)
Oct 29, 2025	2025 (Q3)	- / -0.22	-0.163	-32.88% (-0.05)	―
Aug 26, 2025	2025 (Q2)	- / 0.07	-0.23	128.27% (+0.30)	―	―
Apr 29, 2025	2025 (Q1)	- / -0.20	-0.131	-49.66% (-0.06)	―	―
Feb 27, 2025	2024 (Q4)	- / -0.20	-0.163	-20.33% (-0.03)	―
Oct 31, 2024	2024 (Q3)	- / -0.16	-0.119	-36.85% (-0.04)	―
Aug 29, 2024	2024 (Q2)	- / -0.23	-0.148	-55.40% (-0.08)	―	―
Apr 24, 2024	2024 (Q1)	- / -0.13	-0.124	-5.71% (>-0.01)	―	―
Feb 22, 2024	2023 (Q4)	- / -0.16	-0.133	-22.39% (-0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BOVNF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 26, 2026	$3.29	$3.29	0.00%
Oct 29, 2025	$3.29	$3.29	0.00%
Aug 26, 2025	$3.29	$3.29	0.00%
Apr 29, 2025	$3.06	$3.21	+4.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioInvent International AB (BOVNF) report earnings?

BioInvent International AB (BOVNF) is schdueled to report earning on Apr 29, 2026, Before Open (Confirmed).

What is BioInvent International AB (BOVNF) earnings time?

BioInvent International AB (BOVNF) earnings time is at Apr 29, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BOVNF EPS forecast?

Currently, no data Available